Clinical Trials Directory

Trials / Unknown

UnknownNCT05729464

Risk Factors and Prediction Model of Cancer-associated Venous Thromboembolism

Status
Unknown
Phase
Study type
Observational
Enrollment
700 (estimated)
Sponsor
Yongsheng Jiang · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to identify risk factors of cancer-associated venous thrombosis and develop a prediction model to assist clinicians in tailoring anticoagulant therapy.

Detailed description

Venous thromboembolism (VTE) is a prevalent complication in cancer patients. Compared with the general population, patients with tumors are four to seven times more likely to develop venous thrombotic events. A population-based cohort study showed that the incidence of VTE in these patients has increased steadily over the past decade. Cancer-associated thrombosis may result in discontinuation of antineoplastic therapy, decreased quality of life, and increased mortality. Clinical trials indicate that prophylactic anticoagulation leads to a significantly lower rate of thrombotic disorders. However, due to the fact that thromboprophylaxis treatment increases the risk of bleeding complications and that the risk of VTE varies widely among individuals, only patients at high risk of thrombosis will benefit from primary thromboprophylaxis. In this setting, the use of anticoagulant drugs is challenging. So, the purpose of this study is to identify risk factors of cancer-associated venous thrombosis and develop a prediction model to assist clinicians in tailoring anticoagulant therapy.

Conditions

Timeline

Start date
2022-12-23
Primary completion
2023-07-01
Completion
2023-12-30
First posted
2023-02-15
Last updated
2023-02-15

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05729464. Inclusion in this directory is not an endorsement.